Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 46, Issue 1, Pages 10-20Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0091270005283282
Keywords
efalizumab; pharmacokinetics; pharmacodynamics; psoriasis; anti-CD11a
Categories
Ask authors/readers for more resources
Efalizumab is a recombinant humanized monoclonal IgG(1) antibody shown to be efficacious for the treatment of moderate to severe chronic plaque psoriasis. Efalizumab, a targeted inhibitor of T cell interactions, binds to the GD11a subunit of lymphocyte function-associated antigen I (LFA-1), thereby preventing LFA-1 binding to intercellular adhesion molecule 1 (ICAM-1). The authors review the pharmacokinetic and pharmacodynamic data from the efalizumab clinical development program and discuss how these data led to selection of the optimal weekly subcutaneous (SC) dose of efalizumab (1.0 mg/kg) in adults. Efalizumab SC dosages of 1.0 mg/kg/wk or greater excited maximal pharmacodynamic effects for CD11a expression and available CD11a binding sites on T lymphocytes. Dosages greater than 1.0 mg/kg/wk SC did not provide additional benefits; moreover, higher doses did not alter the safety profile. During long-term administration Of efslizumab, serum levels were generally stable and pharmacodynamic markers remained maximally affected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available